Form PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number	102286.123	Application Number	09/746,662

Applicant
Turski, et al.

Filing Date	Group Art Unit
December 22, 2000	~~1614~~ 164(

Sheet	1	OF	1

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RLi	6,277,850	Aug. 21, 2001	Lubisch, et al.	514	249	

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
RLi	EP 0 878 196	Nov. 18, 1998	EP				
	EP 1 153 922	Nov.14, 2001	EP				
	99/31051	Jun. 24, 1999	WO				
	99/38841	Aug. 5, 1999	WO				
	98/20864	May 22, 1998	WO				
	00/74676	Dec. 14, 2000	WO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

RLi	B1	Pitt, et al., "Glutamate Excitotoxicity in a Model of Multiple Sclerosis" *Nature Medicine,* Vol. 4 (1), pp. 67-70 (1999)
	B2	Prineas, et al., "Demyelinating Diseases*", Greenfield's Neuropathology* Chapter 13, pp. 813-896 (1997)
	B3	Piani, et al., "Murine Brain Macrophages Induce NMDA Receptor Mediated Neurotoxicity In Vitro by Secreting Glutamate" *Neuroscience Letters,* Vol. 133, pp. 159-162 (1991)
	B4	Werner, et al., "Glutamate Excitotoxicity – A Mechanism For Axonal Damage and Oligodendrocyte Death in Multiple Sclerosis?", *Adv. Res. Neurodegener,* Vol. 8, pp. 375-385 (2000)
	B5	Smith, et al., "Autoimmune Encephalomyelitis Ameliorated by AMPA Antagonists" *Nature Medicine,* Vol. 6 (1), pp. 63-66 (2000)
	B6	Matute, et al. "The Link Between Excitotoxic Oligodendroglial Death and Demyelinating Diseases" *TRENDA in Neurosciences,* Vol. 24 (4) pp. 224-230 (2001)

EXAMINER	DATE CONSIDERED
Ruixiang Li	3/30/2003

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1550050v1